The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 11 I, 2005, Pages 2563-2568

  Xu, Jianfeng ^a   Lowey, James ^b   Wiklund, Fredrik ^e   Sun, Jielin ^a   Lindmark, Fredrik ^e   Hsu, Fang Chi ^a   Dimitrov, Latchezar ^a   Chang, Baoli ^a   Turner, Aubrey R ^a   Liu, Wennan ^a   Adami, Hans Olov ^f   Suh, Edward ^b   Moore, Jason H ^c   Zheng, S Lilly ^a   Isaacs, William B ^d   Trent, Jeffrey M ^b   Grönberg, Henrik ^e  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e UMEÅ UNIVERSITY   (Sweden)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CYTOKINE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; PROTEIN TIRAP; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 5; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CONTROLLED STUDY; ERROR; GENE INTERACTION; GENOTYPE; HAPLOTYPE; HUMAN; INFLAMMATION; MALE; MUTATIONAL ANALYSIS; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; SWEDEN; VALIDATION PROCESS;

CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; INFLAMMATION; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATIC NEOPLASMS; REGISTRIES; RISK FACTORS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 28644433425     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0356     Document Type: Article

References (25)

1. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;13:R103-21.
2. Zheng SL, Augustsson-Balter K, Chang B, et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res 2004;24:2918-22.
3. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
4. Weir BS. Sunderland, (MA): Sinauer Association; 1996.
5. Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001;69:138-47.
6. Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 2003;19:376-82.
7. Ritchie MD, Hahn LW, Moore JH. Power of multifactor dimensionality reduction for detecting gene-gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet Epidemiol 2003;24:150-7.
8. Moore JH. Computational analysis of gene-gene interactions using multifactor dimensionality reduction. Expert Rev Mol Diagn 2004;4:795-803.
9. Moore JH. The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum Hered 2003;56:73-82.
10. Nelson MR, Kardia SL, Ferrell RE, Sing CF. A combinatorial partitioning method to identify multilocus genotypic partitions that predict quantitative trait variation. Genome Res 2001;1:458-70.
11. Thornton-Wells TA, Moore JH, Haines JL. Genetics, statistics and human disease: analytical retooling for complexity. Trends Genet 2004;20:640-7.
12. Tsai CT, Lai LP, Lin JL, et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004;109:1640-6.
13. Cho YM, Ritchie MD, Moore JH, et al. Multifactor-dimensionality reduction shows a two-locus interaction associated with Type 2 diabetes mellitus. Diabetologia 2004;47:549-54.
14. Williams FM, Cherkas LF, Spector TD, MacGregor AJ. A common genetic factor underlies hypertension and other cardiovascular disorders. BMC Cardiovasc Disord 2004;4;20.
15. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
16. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
17. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81.
18. Nelson WG, DeWeese TL, DeMarzo AM. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 2002;21:3-16.
19. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999;155:1985-92.
20. Shah R, Mucci NR, Amin A, Macoska JA, Rubin MA. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 2001;158:1767-73.
21. Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002;302:181-4.
22. Xu J, Zheng SL, Komiya A, et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002;32:321-5.
23. Sun J, Wiklund F, Zheng SL, et al. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 2005;97:525-32.
24. Lindmark F, Zheng SL, Wiklund F, et al. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 2004;96:1248-54.
25. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med 1993;118:201-10.